2027 ICD-10-CM Diagnosis Code C72.9Malignant neoplasm of central nervous system, unspecified
ICD-10-CM Codes›C00–D49›C69-C72›C72
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 20
- Chronic Condition
C72.9 is a billable ICD-10-CM diagnosis code for malignant neoplasm of central nervous system, unspecified. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 54 through 55. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 47 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Nervous system cancers - all other types.
For Medicare Advantage risk adjustment, C72.9 maps to CMS-HCC Category 20 (Lung and Other Severe Cancers) under the V28 model, adding a risk factor of about 1.136 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C72.9 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Anaplastic astrocytoma of central nervous system
- Anaplastic ependymoma of central nervous system
- Anaplastic ganglioglioma
- Anaplastic ganglioglioma of central nervous system
- Anaplastic oligoastrocytoma of central nervous system
- Anaplastic oligodendroglioma of central nervous system
- Angiocentric glioma of central nervous system
- Astroblastoma of central nervous system
- Choriocarcinoma
- Embryonal neoplasm with multilayered rosettes
- Ependymoblastoma
- Ependymoma of central nervous system
- Fibrillary astrocytoma of central nervous system
- Ganglioneuroblastoma
- Ganglioneuroblastoma of central nervous system
- Gemistocytic astrocytoma of central nervous system
- Germinoma of central nervous system
- Giant cell glioblastoma of central nervous system
- Glioblastoma multiforme of central nervous system
- Glioma
- Glioma of central nervous system
- Gliosarcoma of central nervous system
- Malignant glioma of central nervous system
- Malignant neoplasm of central nervous system
- Malignant neoplasm of nervous system
- Malignant nongerminomatous germ cell neoplasm of central nervous system
- Medulloepithelioma
- Medulloepithelioma of central nervous system
- Melanoma and neural system tumor syndrome
- Metastatic malignant glioma
- Mixed germ cell neoplasm
- Mixed germ cell neoplasm of central nervous system
- Mixed glioma
- Neuroblastoma of central nervous system
- Oligodendroglioma of central nervous system
- Overlapping malignant neoplasm of brain and other parts of the central nervous system
- Pilomyxoid astrocytoma
- Primary anaplastic astrocytoma of central nervous system
- Primary anaplastic ependymoma of central nervous system
- Primary anaplastic ganglioglioma of central nervous system
- Primary anaplastic oligoastrocytoma of central nervous system
- Primary anaplastic oligodendroglioma of central nervous system
- Primary astroblastoma of central nervous system
- Primary choriocarcinoma of central nervous system
- Primary ependymoblastoma
- Primary fibrillary astrocytoma of central nervous system
- Primary ganglioneuroblastoma
- Primary ganglioneuroblastoma of central nervous system
- Primary gemistocytic astrocytoma of central nervous system
- Primary giant cell glioblastoma of central nervous system
- Primary glioblastoma multiforme of central nervous system
- Primary gliosarcoma of central nervous system
- Primary malignant astrocytoma of central nervous system
- Primary malignant atypical teratoid rhabdoid neoplasm of central nervous system
- Primary malignant glioma of central nervous system
- Primary malignant melanoma of central nervous system
- Primary malignant neoplasm of central nervous system
- Primary malignant neoplasm of nervous system
- Primary medulloepithelioma
- Primary medulloepithelioma of central nervous system
- Primary mixed germ cell neoplasm
- Primary mixed germ cell neoplasm of central nervous system
- Primary mixed glioma
- Primary neuroblastoma
- Primary neuroblastoma of central nervous system
- Primary oligodendroglioma
- Primary primitive neuroectodermal neoplasm of central nervous system
- Primary primitive neuroectodermal tumor
- Yolk sac tumor
- Yolk sac tumor of central nervous system
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C72.9: its own notes plus those printed at C72 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Malignant neoplasm of unspecified site of central nervous system
- Malignant neoplasm of nervous system NOS
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C72.9, its category, or a range that includes it.
Applicable To 2
These notes mention C72.9.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Malignant Central Nervous System Neoplasm
a primary or metastatic malignant neoplasm involving the brain or spinal cord. representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
Patient EducationClinical
Cancer
Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should.
The full article covers:
- What is cancer?
- What are the types of cancer?
- How does cancer develop?
- What are the symptoms of cancer?
- How is cancer diagnosed?
- What are the treatments for cancer?
- Can cancer be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C72.9 to ICD-9-CMHistory
Code HistoryHistory
Questions About C72.9Overview
What is the ICD-10 code for malignant neoplasm of central nervous system, unspecified?
The ICD-10-CM code for malignant neoplasm of central nervous system, unspecified is C72.9 (sometimes written as C729). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C72.9 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of central nervous system, unspecified on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C72.9 group to?
When malignant neoplasm of central nervous system, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 55, 54, with relative weights from 1.0291 to 1.5197 depending on complications. Higher weights mean higher Medicare reimbursement.
Is C72.9 a CC or MCC?
CMS lists C72.9 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 47 closely related codes in its exclusion list.
Can C72.9 be reported with a code from C70?
Not as a rule. The Excludes1 note at C72, which applies to C72.9, lists "malignant neoplasm of meninges (C70.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What HCC is C72.9?
C72.9 (malignant neoplasm of central nervous system, unspecified) maps to CMS-HCC Category 20 (Lung and Other Severe Cancers), commonly written as HCC 20, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 10 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C72.9 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C72.9 adds a risk adjustment factor of about 1.136 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.672 to 1.214 depending on the payment segment). A more severe related category (HCC 17, HCC 18, and HCC 19) supersedes it when both are reported. See the full factor table on the HCC 20 category page.
